HOME >> MEDICINE >> NEWS
Phase II trial of anthrax vaccine to begin

Center for Vaccine Research needs volunteers for Phase II Trial of anthrax vaccine candidate

(Torrance, CA April 22, 2004) The UCLA Center for Vaccine Research, a leading research program at the Research and Education Institute (REI) at Harbor UCLA Medical Center, announced today that it has initiated a Phase II trial of a new anthrax vaccine, rPA102 (VaxGen, Inc.). The 13-month trial is taking place at 12 medical centers in the United States and is one of two studies of rPA102 initiated this year under a multi-year, $80.3 million U.S. government contract to VaxGen, Inc. from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

VaxGen, Inc. began developing rPA102 to address the need for an anthrax vaccine that has an improved safety profile and a more practical dosing schedule compared to the existing licensed anthrax vaccine. rPA is a synthetic protein vaccine that induces antibodies that are designed to prevent illness by neutralizing anthrax toxins. rPA102 cannot cause anthrax infection. The goal of this study is to determine the optimal formulation of the rPA vaccine that will provide an early and protective immune response.

Healthy adults, 18 to 55 years of age, who have not received an anthrax vaccine and have not been exposed to anthrax, are needed to participate in this study. Participants will need to be available for 14 visits to the clinic (Torrance) over a one-year period. Participants will be compensated up to $700 for completion of study visits.

For further information on how to take part in this trial, please call 1-800-637-8860.


'"/>

Contact: Susan Partridge, BSN, MBA
partridge@humc.edu
310-781-3630
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
22-Apr-2004


Page: 1

Related medicine news :

1. Elan and Biogen Idec announce results from Phase III maintenance trial of Antegren
2. NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed
3. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
4. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
5. Penn researchers announce results of Phase I trial using combretastatin drug
6. Anti-cocaine vaccine produces antibodies and is shown to be safe in Phase 1 study conducted by Yale researcher
7. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions
8. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
9. Abgenix Reports Positive Survival Data From A Phase II Trial Of ABX-CBL In Graft Versus Host Disease
10. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
11. Positive Results Of Pivotal Phase III Trial With ENBREL In Patients With Early, Active Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/22/2018)... ... 2018 , ... "Business Matrix" is a show hosted by a successful actor, ... program will focus on sports injury prevention. , Sports are a great way to ... have fun or compete professionally. Unfortunately, all sports have some level of injury risks. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... throughout Arkansas that offers insurance and financial preparation services, is providing an update ... City Rescue organization. , Rock City Rescue is a locally recognized nonprofit that ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology:
Cached News: